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a b s t r a c t
Yellow fever (YF) is a mosquito-borne viral hemorrhagic fever, which is a serious and
potentially fatal disease with no speciﬁc antiviral treatment that can be effectively pre-
vented by an attenuated vaccine (YEL). Despite the long history of safe and efﬁcacious YF
vaccination, sporadic case reports of serious adverse events (SAEs) have been reported,
including yellow fever vaccine-associated neurotropic disease (YEL-AND). YEL-AND usually
appears within one month of YF vaccination, manifesting as meningoencephalitis, Guillain–
Barré syndrome (GBS) or acute disseminated encephalomyelitis (ADEM). We report a case of
YEL-AND with meningitis presentation in a 39-year-old Caucasian man without evidence of
signiﬁcant risk factors, which was conﬁrmed by the presence of the YF virus and speciﬁc
immunoglobulin G (IgG) antibodies in the cerebrospinal ﬂuid (CSF). In conclusion, we should
stress the importance of balancing the risk of SAEs associated with the vaccine and the
beneﬁts of YF vaccination for each patient individually.
# 2016 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Yellow fever (YF) is a viral hemorrhagic fever, which is a
vector-borne disease resulting from transmission of the
yellow fever virus (YFV) to a human from the bite of an
infected mosquito, Aedes or Haemagogus species [1,2]. YFV is a
single-stranded ribonucleic acid (RNA) virus that belongs to
the genus Flavivirus [1,2]. YF is endemic to sub-Saharan Africa
and tropical South America and is estimated to cause 200,000
cases of clinical disease and 30,000 deaths annually [1,2].
Clinically, the disease varies from a mild, undifferentiated
febrile illness to a severe disease with jaundice, hemorrhagic* Corresponding author at: Department of Neurology, Poznan Univers
Poland. Tel.: +48 61 8691 454; fax: +48 61 8691 697.
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0028-3843/# 2016 Polish Neurological Society. Published by Elsevier Smanifestation and hepatorenal failure marked by a case-
fatality ratio of 20–50% [1–3]. Differences in viral strains and
host immune factors are probably responsible for the range of
clinical symptoms [1]. Because no speciﬁc antiviral treatment
exists for YF, prevention is critical to lower disease morbidity
and mortality. All residents and travelers to areas in which YF
is endemic should be warned of the risk of contracting the
disease and should be advised about available preventive
measures [2]. Immunization, supplemented with prevention
of mosquito bites, is now the most important method of YF
prevention [1]. Vaccines against YF have been available since
the 1940s and are responsible for a signiﬁcant reduction of
disease occurrence [1,4].ity of Medical Sciences, Przybyszewskiego 49 St., 60-355 Poznan,
p. z o.o. All rights reserved.
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and 17D-204 [1,2]. The live attenuated YF vaccine (YEL) is one of
the safest and most efﬁcacious vaccines ever made [5].
Seroconversion occurs in >95% of recipients by 10 days after
vaccination [2,5]. According to the World Health Organiza-
tion's (WHO) International Health Regulations (IHRs), the
certiﬁcate of immunization for travelers is valid for 10 years
after the most recent YF vaccination [4]. Neutralizing
antibodies (NAs) against YFV, estimated by means of a plaque
reduction neutralization test (PRNT), are considered to be the
best surrogate marker for protection against YF [4,6]. Despite a
long history of safe and efﬁcacious YF vaccination, sporadic
cases of serious adverse events (SAEs) have been reported,
including severe allergic reactions, neurotropic disease (yel-
low-fever vaccine-associated neurotropic disease, YEL-AND)
and viscerotropic disease (yellow-fever vaccine-associated
viscerotropic disease, YEL-AVD) [3,4]. The last one is especially
notable for its lethality [7]. YEL-AVD is an acute multi-organ
dysfunction resembling a fulminant infection by wild-type
YFV, with manifestations that include fever, jaundice, hepati-
tis, renal failure, thrombocytopenia, bleeding dyscrasia and
respiratory failure [8]. Incidence of YEL-AVD is approximately
0.4 per 100,000 doses of vaccine administered, and the case-
fatality ratio is estimated at 65% [2,9,11]. YEL-AND appears
typically within one month after YF vaccination, manifesting
itself as meningoencephalitis, Guillain–Barré syndrome (GBS)
or acute disseminated encephalomyelitis (ADEM) [2,10]. Its
estimated incidence is 0.4–0.8 per 100,000 doses administered
[2,9,11]. Although the majority of patients recover without
sequelae [1–3], a few reports of fatal YEL-AND have been
published [5,8,10]. The meningoencephalitis cases were
considered to deﬁnitely have been caused by the YF vaccine
if 17D-204 YFV was isolated from the cerebrospinal ﬂuid (CSF)
and/or 17D-204 YFV RNA was ampliﬁed from CSF by nucleic
acid-ampliﬁcation testing (for example RT-PCR, reverse-
transcription polymerase chain reaction), or the YFV-speciﬁc
immunoglobulin M (IgM) antibody was found in CSF by IgM-
capture ELISA [2,5,10]. ADEM and GBS are thought to be
associated with autoimmune mechanisms in which patho-
genic autoantibodies are generated in response to an
antecedent stimulus [2,10].
The YF vaccine is contraindicated in several situations, e.g.
in allergy to YF vaccine components, age <6 months,
symptomatic human immunodeﬁciency virus (HIV) infection
or CD4 T-lymphocyte count <200 cells/mm3, thymus disorders
associated with abnormal immune cell function, primary
immunodeﬁciency, malignant neoplasm, organ transplanta-
tion, and immunosuppressive or immunomodulatory therapy
[2,4]. Precautions for its use include an age of 6–8 months,
an age over 60 years, asymptomatic HIV infection and a CD4 T-
lymphocyte count of 200–499 cells/mm3, pregnancy and
breast-feeding [2,3,12].
One of the vaccines available against YF is the live,
attenuated, 17D-204 vaccine Stamaril® (Sanoﬁ, Pasteur,
France), which is available in more than 100 countries,
including in Europe, with a licence since 1983 [3]. In the last
20 years of pharmacovigilance surveillance, only six cases of
deﬁnite YEL-AND have been reported worldwide following
Stamaril® vaccination for approximately 392 million
doses distributed [3]. Since marketing authorization in 1996,approximately 236,000 doses of the Stamaril® vaccine have
been distributed in Poland, and a total of 3 cases of SAEs as per
international recommendations [13], has been reported in
Poland.
2. Case report
A 39-year-old Caucasian man was admitted to the neurological
ward due to severe headache, malaise and increasing fever for
a few days ranging from 37.5 to 39 8C. Two weeks before
admission the patient had been vaccinated against YF with
Stamaril® for the ﬁrst time in his life due to a planned journey
to Panama. The above-mentioned symptoms commenced ﬁve
days after the vaccination. There was also a history of frequent
sinusitis, and the last infection had taken place one month
before the YF vaccination. Generally, the patient was in good
health, without chronic illnesses, including thymus disorders
and primary immunodeﬁciency, or any necessity of chronic
treatment. On admission, the patient's neurological examina-
tion, basic laboratory tests of blood and urine, X-ray of the
chest and paranasal sinuses, electroencephalography (EEG) as
well as computerized tomography (CT) of the head showed no
abnormalities. The CSF examination revealed lymphocytic
cytosis, 448 cells per mm3, while the protein and glucose
concentrations were within normal limits, and oligoclonal
bands were absent. Based on the clinical picture and CSF
examination, the diagnosis of meningitis was made and
empiric therapy with acyclovir and ceftriaxone was started. On
the second day of hospitalization, signs of a stiff neck,
hyperreﬂexia and pain in the cervical and thoracic region of
the vertebral column appeared. Magnetic resonance imaging
(MRI) studies of the brain, cervical and thoracic spinal cord
were ordered and, except for intensive meningeal contrast
enhancement in the cervical localization, no abnormalities
were found. Ultrasonography (USG) of the abdomen, CT of the
chest and abdomen were all within normal limits. Subsequent
extensive investigations from the blood, urine and CSF for
infection (bacteria, fungi and viruses, including HIV) were all
negative with the exception of YF. The analyses of serum and
CSF samples performed on the 20th and 15th day post-
vaccination for YFV by RT-PCR were negative in the serum and
positive in CSF. Moreover, the results obtained on the 20th day
post-vaccination were negative for the presence of speciﬁc IgM
and IgG antibodies in CSF while positive for both classes of
antibodies in the serum (see Table 1). On the 7th day after
admission, due to a worsening of the patient's clinical status,
with fever up to 39.9 8C and severe headache, intravenous
immunoglobulin (IVIG, 0.4 g/kg/day) therapy was introduced
for three days with good effect. Subsequently, empiric therapy
was stopped and only supportive therapy was continued. The
control lumbar puncture performed on the 19th day of
hospitalization (32nd day post-vaccination) revealed a signiﬁ-
cant decrease in cytosis to 23 cells/mm3, with normal glucose
and protein concentrations. Control analyses of serum, CSF
and urine for YFV, and speciﬁc IgM and IgG antibodies in the
serum and CSF were conducted, revealing the presence of IgG
antibodies in the serum and in CSF (see Table 1). In the
meantime, a transient yet signiﬁcant increase of liver enzymes
was observed. A number of diagnostic procedures as well as
Table 1 – Results of serum, CSF and urine analyses estimating YFV presence and serological assay performed in the Robert
Koch-Insitute, Berlin, Germany.
Samples RT-PCR Serological assay
Collected Type 50-NC assay IIF IgM IIF IgG YF PRNT
18.02.2015 Serum Negative Positive Positive Positive (1:83)
02.03.2015 Serum Negative Negative Positive Positive (1:320)
13.02.2015 CSF Positive Negative Negative NP
02.03.2015 CSF Negative Negative Positive Negative
02.03.2015 Urine Negative NP NP NP
IIF – indirect immunoﬂuorescence; RT-PCR – reverse-transcription polymerase chain reaction; PRNT – plaque reduction neutralization test.
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performed, conﬁrming that the increase was associated with
drug-induced damage of the liver. Based on the clinical picture,
the temporal association with YF vaccination, course of the
disease, parasitological consultation, laboratory tests and EEG
and MRI studies, YEL-AND with meningitis manifestation was
ﬁnally diagnosed. A gradual improvement of the patient's
clinical status was observed and he was discharged from the
hospital without sequelae except for a mild headache.
The case was reported to the manufacturer Sanoﬁ Pasteur
in Poland and in France via Vaccine Adverse Events Reporting/
Pharmacovigilance System and was classiﬁed as meeting the
deﬁnite YEL-AND criteria, according to Centers for Disease
Control and Prevention (CDC), 2010 [2,a letter from Global
Pharmacovigilance Department of Sanoﬁ Pasteur, Lyon,
France].
3. Discussion
17D YF vaccines (17D-204 and 17DD) are well tolerated and the
rate of post-vaccination SAEs is, generally, low [2,3,14,15]. In
healthy persons the onset of viremia occurs within 2–7 days
after primary YF vaccination, lasting an average of 2–5 days
[2,5,12], while in patients with YEL-AEs this timing can be
prolonged [5]. Cases of YEL-AND have been the most common
SAEs associated with YF vaccination [16] and are estimated to
occur in 0.4 per 100,000 vaccines [10]. However, fortunately
most patients suffering from YEL-AND recover well [3,10].
Cases of YEL-AND are classiﬁed as neurotropic disease
(meningoencephalitis) or neurological autoimmune disease
[2,14]. Meningoencephalitis is diagnosed when the 17D YF
virus (YF 17D virus isolation from CSF or, like in our patient,
17D YFV RNA presence in CSF detected by nucleic acid-
ampliﬁcation test, by means of RT-PCR) or positive IgM for YF
on CSF are found, which suggests direct YF vaccine viral
invasion of the CNS and intrathecal antibody production
[2,12,14,17,18]. YFV IgM antibodies are not believed to cross the
blood–brain barrier normally [2]. The sole detection of IgG
would only conﬁrm a previous contact with YFV or with
another ﬂavivirus as serological cross-reactivity [19]. In the
case we reported there was coexistence of the typical clinical
picture, the temporal association with YF vaccination, positive
RT-PCR for YFV in CSF and presence of IgG in the second but
not in the ﬁrst CSF specimen, what conﬁrmed the current
production of speciﬁc IgG in CSF. Neurological autoimmune
disease may present itself as GBS, ADEM, transverse myelitisand bilateral optic neuritis [2,17], and a combination of all of
the above-mentioned conditions can occur [2,17]. No speciﬁc
test is available for the autoimmune-mediated syndromes. A
diagnosis of these conditions should be made using appropri-
ate studies (e.g. neuroimaging, EEG, electromyography and
nerve conduction studies) [2,10]. An autoimmune manifesta-
tion of YEL-AND is associated with the production of speciﬁc
antibodies and/or a T-cell response as a result of the molecular
mimicry mechanism, when T-cells mistakenly recognize
vaccine epitopes as neuronal ones, which leads to central or
peripheral nerve damage [2]. The mechanisms underlying the
development of these AEs remain unknown and probably
include viral and host features [5,14,18]. It is generally
considered that host factors, mainly host immune responses
to the 17D YF vaccine, may represent the major causes of YEL-
SAEs [5,14,18]. An immature blood–brain barrier, the degree of
viremia and immaturity of the immune system are the most
probable reasons for YEL-AND in infants [2,12]. Also, advanced
age (60 years and older), a history of thymus disorder,
immunosuppression, male gender and a ﬁrst-time YF vacci-
nation are vital risk factors for SAE after YF vaccination
[2,5,12,16,20]. Likewise, naturally acquired YF is more likely to
be severe among males [21]. A higher humoral immune
response in men may be due to higher viremia, accompanied
by a higher rate of AEs in men than in women [5]. On the
contrary, patients who were previously vaccinated against YF
are at lower risk of YEL-AND [16]. Roukens et al. postulated that
older patients have a weaker immune response to the YF
vaccine, which allows the attenuated virus to cause higher
viremia levels and increases the risk of developing SAEs [22].
Yet not only the 17D YF vaccination virus may be responsible
directly for YEL-AEs in vaccinated persons, as transmission of
the vaccine strain of YF via breastfeeding [12] or blood products
after vaccination of the donor were reported, showing the risk
of contact with body ﬂuids through the parenteral route [23].
However, several cases with unknown risk factors have been
reported [14], and our case seems to be included in that
number. The only risk factor identiﬁed in our patient could
have been the preceding sinusitis one month before the YF
vaccination which could have altered his immune system to
some extent. Treatment for YEL-AND depends on the clinical
syndrome [2]. For meningoencephalitis, the only treatment is,
in fact, supportive therapy, while for GBS IVIG or plasma
exchange, and for ADEM corticosteroids, IVIG or plasma
exchange are recommended [2]. Healthcare providers need
to balance the risk of SAEs associated with the vaccine and the
beneﬁts of YF vaccination for each patient individually [8]. A
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further clinical evaluation [4]. If the live-attenuated 17D
vaccine could be replaced with the new one in the near future
this would most likely decrease the difﬁculty in decision
making before using YF vaccination, especially in immuno-
compromised individuals [4].
4. Conclusions
Although the risk of SAE incidence after YF vaccination is low
[24,25], it is necessary to limit it as much as possible due to the
likely fatal sequelae. Further investigations and assessments
of YEL-AE cases are necessary to improve our understanding
and methods of prevention. The YF vaccine ought to be
administered to a person at risk based on reports of epidemic
activity, season, duration of travel and the overall likelihood of
exposure to vector mosquitoes [2,16,26].
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